Intermittent preventive treatment in infants as a means of malaria control: a randomized, double-blind, placebo-controlled trial in northern Ghana

Frank P Mockenhaupt, Klaus Reither, Philipp Zanger, Felix Roepcke, Ina Danquah, Eiman Saad, Peter Ziniel, Stephen Y Dzisi, Marc Frempong, Patrick Agana-Nsiire, Felicia Amoo-Sakyi, Rowland Otchwemah, Jakob P Cramer, Sylvester D Anemana, Ekkehart Dietz, Ulrich Bienzle, Frank P Mockenhaupt, Klaus Reither, Philipp Zanger, Felix Roepcke, Ina Danquah, Eiman Saad, Peter Ziniel, Stephen Y Dzisi, Marc Frempong, Patrick Agana-Nsiire, Felicia Amoo-Sakyi, Rowland Otchwemah, Jakob P Cramer, Sylvester D Anemana, Ekkehart Dietz, Ulrich Bienzle

Abstract

Morbidity and mortality from malaria remain unacceptably high among young children in sub-Saharan Africa. Intermittent preventive treatment in infancy (IPTi) involves the administration of antimalarials alongside routine vaccinations and might be an option in malaria control. In an area of intense, perennial malaria transmission in northern Ghana, 1,200 children received IPTi with sulfadoxine-pyrimethamine or placebo at approximately 3, 9, and 15 months of age. Children were followed up until 24 months of age to assess morbidity and adverse events. During the intervention period (3 to 18 months of age), IPTi reduced the incidences of malaria and severe anemia by 22.5% (95% confidence interval, 12 to 32%) and 23.6% (95% confidence interval, 4 to 39%), respectively, and reduced hospitalizations and episodes of asymptomatic parasitemia by one-third. Protection was pronounced in the first year of life and not discernible in the second. The malaria-protective effect was largely confined to a period of 1 month after sulfadoxine-pyrimethamine treatments. Following the intervention, protection against asymptomatic parasitemia persisted. In contrast, a significant rebound of severe malaria, predominantly severe malarial anemia, occurred among children having received IPTi. Although the treatment was generally well tolerated, one case of moderately severe skin reaction followed sulfadoxine-pyrimethamine treatment. IPTi reduces malaria and anemia in infants in northern Ghana. Extension of IPTi into the second year of life by administering a dose at 15 months of age provided no substantial benefit beyond a 1-month prophylactic effect. Although this simple intervention offers one of the few available malaria-preventive measures for regions where malaria is endemic, the observed rebound of severe malaria advises caution and requires further investigation.

Figures

FIG. 1.
FIG. 1.
Trial profile.
FIG. 2.
FIG. 2.
Kaplan-Meier survival estimates of the proportions of children free of malaria (A) and severe anemia (B) by treatment group.

References

    1. Alexander, N., C. Sutherland, C. Roper, B. Cisse, and D. Schellenberg. 2007. Modelling the impact of intermittent preventive treatment for malaria on selection pressure for drug resistance. Malar. J. 6:9.
    1. Beck, H. P., I. Felger, P. Vounatsou, R. Hirt, M. Tanner, P. Alonso, and C. Menendez. 1999. Effect of iron supplementation and malaria prophylaxis in infants on Plasmodium falciparum genotypes and multiplicity of infection. Trans. R. Soc. Trop. Med. Hyg. 93(Suppl. 1):41-45.
    1. Bereczky, S., A. Liljander, I. Rooth, L. Faraja, F. Granath, S. M. Montgomery, and A. Färnert. 2007. Multiclonal asymptomatic Plasmodium falciparum infections predict a reduced risk of malaria disease in a Tanzanian population. Microbes Infect. 9:103-110.
    1. Breman, J. G. 2001. The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. Am. J. Trop. Med. Hyg. 64(Suppl. 1-2):1-11.
    1. Breman, J. G., M. S. Alilio, and A. Mills. 2004. Conquering the intolerable burden of malaria: what's new, what's needed: a summary. Am. J. Trop. Med. Hyg. 71(Suppl. 2):1-15.
    1. Chandramohan, D., S. Owusu-Agyei, I. Carneiro, T. Awine, K. Amponsa-Achiano, N. Mensah, S. Jaffar, R. Baiden, A. Hodgson, F. Binka, and B. Greenwood. 2005. Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. BMJ 331:727-733.
    1. de Onis, M., and M. Blossner. 2003. The World Health Organization Global Database on Child Growth and Malnutrition: methodology and applications. Int. J. Epidemiol. 32:518-526.
    1. Dicko, A., S. Sagara, M. S. Sissoko, O. Guindo, A. B. I. Diallo, M. Kone, M. A. Thera, M. Sacko, and O. K. Doumbo. 2004. Impact of intermittent preventive treatment with sulfadoxine pyrimethamine targetting the transmission season on the incidence of clinical malaria in children of 6 months to 10 years in Kambila, Mali, abstr. 18. Abstr. 53rd Annu. Meet. Am. Soc. Trop. Med. Hyg.
    1. Dzisi, S. Y. 2002. Childhood malaria in the Bulpeila subdistrict of Tamale, northern Ghana: a study on knowledge, perceptions and attitudes, and socio-demographic factors among care givers. . thesis. Charité—University Medicine Berlin, Berlin, Germany.
    1. Ehrhardt, S., G. D. Burchard, C. Mantel, J. P. Cramer, S. Kaiser, M. Kubo, R. Otchwemah, U. Bienzle, and F. P. Mockenhaupt. 2006. Malaria, anemia, and malnutrition in African children—defining intervention priorities. J. Infect. Dis. 194:108-114.
    1. Geerligs, P. D., B. J. Brabin, and T. A. Eggelte. 2003. Analysis of the effects of malaria chemoprophylaxis in children on haematological responses, morbidity and mortality. Bull. W. H. O. 81:205-216.
    1. Ghana Health Service. 2004. Standard treatment guidelines, 5th ed. Ghana National Drugs Programme, Accra, Ghana.
    1. Greenwood, B. 2007. Intermittent preventive antimalarial treatment in infants. Clin. Infect. Dis. 45:26-28.
    1. Greenwood, B., K. Marsh, and R. Snow. 1991. Why do some African children develop severe malaria? Parasitol. Today 7:277-281.
    1. Greenwood, B. M., P. H. David, L. N. Otoo-Forbes, S. J. Allen, P. L. Alonso, J. R. Armstrong Schellenberg, P. Byass, M. Hurwitz, A. Menon, and R. W. Snow. 1995. Mortality and morbidity from malaria after stopping malaria chemoprophylaxis. Trans. R. Soc. Trop. Med. Hyg. 89:629-633.
    1. Gupta, S., R. W. Snow, C. A. Donnelly, K. Marsh, and C. Newbold. 1999. Immunity to non-cerebral severe malaria is acquired after one or two infections. Nat. Med. 5:340-343.
    1. Kobbe, R., C. Kreuzberg, S. Adjei, B. Thompson, I. Langefeld, P. A. Thompson, H. H. Abruquah, B. Kreuels, M. Ayim, W. Busch, F. Marks, K. Amoah, E. Opoku, C. G. Meyer, O. Adjei, and J. May. 2007. A randomized controlled trial of intermittent preventive antimalarial treatment in infants. Clin. Infect. Dis. 45:16-25.
    1. Macete, E., P. Aide, J. J. Aponte, S. Sanz, I. Mandomando, M. Espasa, B. Sigauque, C. Dobano, S. Mabunda, M. Dgedge, P. Alonso, and C. Menendez. 2006. Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: a randomized, placebo-controlled trial. J. Infect. Dis. 194:276-285.
    1. Marks, F., V. von Kalckreuth, R. Kobbe, S. Adjei, O. Adjei, R. D. Horstmann, C. G. Meyer, and J. May. 2005. Parasitological rebound effect and emergence of pyrimethamine resistance in Plasmodium falciparum after single-dose sulfadoxine-pyrimethamine. J. Infect. Dis. 192:1962-1965.
    1. Menendez, C., E. Kahigwa, R. Hirt, P. Vounatsou, J. J. Aponte, F. Font, C. J. Acosta, D. M. Schellenberg, C. M. Galindo, J. Kimario, H. Urassa, B. Brabin, T. A. Smith, A. Y. Kitua, M. Tanner, and P. L. Alonso. 1997. Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants. Lancet 350:844-850.
    1. Mockenhaupt, F. P., J. Mandelkow, H. Till, S. Ehrhardt, T. A. Eggelte, and U. Bienzle. 2003. Reduced prevalence of Plasmodium falciparum infection and of concomitant anaemia in pregnant women with heterozygous G6PD deficiency. Trop. Med. Int. Health 8:118-124.
    1. Mockenhaupt, F. P., S. Ehrhardt, J. Burkhardt, S. Y. Bosomtwe, S. Laryea, S. D. Anemana, R. N. Otchwemah, J. P. Cramer, E. Dietz, S. Gellert, and U. Bienzle. 2004. Manifestation and outcome of severe malaria in children in northern Ghana. Am. J. Trop. Med. Hyg. 71:167-172.
    1. Mockenhaupt, F. P., S. Ehrhardt, S. Y. Dzisi, T. J. Bousema, N. Wassilew, J. Schreiber, S. D. Anemana, J. P. Cramer, R. N. Otchwemah, R. W. Sauerwein, T. A. Eggelte, and U. Bienzle. 2005. A randomized, placebo-controlled, double-blind trial on sulfadoxine-pyrimethamine alone or combined with artesunate or amodiaquine in uncomplicated malaria. Trop. Med. Int. Health 10:512-520.
    1. Mockenhaupt, F. P., S. Ehrhardt, T. A. Eggelte, P. Agana-Nsiire, K. Stollberg, A. Mathieu, M. Markert, R. N. Otchwemah, and U. Bienzle. 2005. Chloroquine-treatment failure in northern Ghana: roles of pfcrt T76 and pfmdr1 Y86. Ann. Trop. Med. Parasitol. 99:723-732.
    1. O'Meara, W. P., D. L. Smith, and F. E. McKenzie. 2006. Potential impact of intermittent preventive treatment (IPT) on spread of drug-resistant malaria. PLoS Med. 3:e141.
    1. O'Meara, W. P., J. G. Breman, and F. E. McKenzie. 2005. The promise and potential challenges of intermittent preventive treatment for malaria in infants (IPTi). Malar. J. 4:33.
    1. Pool, R., K. Munguambe, E. Macete, P. Aide, G. Juma, P. Alonso, and C. Menendez. 2006. Community response to intermittent preventive treatment delivered to infants (IPTi) through the EPI system in Manhica, Mozambique. Trop. Med. Int. Health 11:1670-1678.
    1. Schellenberg, D., B. Cisse, and C. Menendez. 2006. The IPTi Consortium: research for policy and action. Trends Parasitol. 22:296-300.
    1. Schellenberg, D., C. Menendez, E. Kahigwa, J. Aponte, J. Vidal, M. Tanner, M. Mshinda, and P. Alonso. 2001. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet 357:1471-1477.
    1. Schellenberg, D., C. Menendez, J. J. Aponte, E. Kahigwa, M. Tanner, H. Mshinda, and P. Alonso. 2005. Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial. Lancet 365:1481-1483.
    1. Shashindran, C. H., I. S. Gandhi, and S. Lal. 1979. A trial of cotrimoxazole in scabies. Br. J. Dermatol. 100:483.
    1. Stoltzfus, R. 1997. Rethinking anaemia surveillance. Lancet 349:1764-1766.
    1. Terlouw, D. J., B. L. Nahlen, J. M. Courval, S. K. Kariuki, O. S. Rosenberg, A. J. Oloo, M. S. Kolczak, W. A. Hawley, A. A. Lal, and F. O. Kuile. 2003. Sulfadoxine-pyrimethamine in treatment of malaria in Western Kenya: increasing resistance and underdosing. Antimicrob. Agents Chemother. 47:2929-2932.
    1. Winstanley, P. A., W. M. Watkins, C. R. Newton, C. Nevill, E. Mberu, P. A. Warn, C. M. Waruiru, I. N. Mwangi, D. A. Warrell, and K. Marsh. 1992. The disposition of oral and intramuscular pyrimethamine/sulphadoxine in Kenyan children with high parasitaemia but clinically non-severe falciparum malaria. Br. J. Clin. Pharmacol. 33:143-148.
    1. World Health Organization. 1986. WHO Expert Committee on Malaria. Eighteenth report. WHO Tech. Rep. Ser. 735:65-66.
    1. World Health Organization. 2000. Severe falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 94(Suppl. 1):1-90.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner